Roivant Sciences (ROIV) FCF Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) FCF Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.13 Bn | 198.14 Bn | 7.24 Bn | 1,388.00 |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 3,383.00 |
| 3 | Vertex Pharmaceuticals | 132.34 Bn | 124.49 Bn | 2.84 Bn | -89.00 |
| 4 | Regeneron Pharmaceuticals | 82.70 Bn | 74.71 Bn | 3.93 Bn | -1,183.00 |
| 5 | Argenx Se | 61.60 Bn | 56.42 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.61 Bn | 49.48 Bn | 52.00 Mn | 26,102.00 |
| 7 | Alnylam Pharmaceuticals | 33.96 Bn | 30.65 Bn | 992.69 Mn | 769.00 |
| 8 | Biogen | 31.26 Bn | 29.97 Bn | 1.96 Bn | 984.00 |
| 9 | Roivant Sciences | 29.96 Bn | 29.96 Bn | 1.16 Mn | -902,489.00 |
| 10 | Insmed | 28.16 Bn | 27.00 Bn | 358.27 Mn | 19,111.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -902,489.00 |
| Dec 31, 2025 | -721,747.00 |
| Sep 30, 2025 | -633,336.00 |
| Jun 30, 2025 | -717,906.00 |
| Dec 31, 2024 | -34,535.00 |
| Sep 30, 2024 | -59,235.00 |
| Jun 30, 2024 | -126,778.00 |
| Dec 31, 2023 | -78,452.00 |
| Sep 30, 2023 | -385,426.00 |
| Jun 30, 2023 | 485,161.00 |
| Dec 31, 2022 | -81,660.00 |
| Sep 30, 2022 | -65,585.00 |
| Jun 30, 2022 | -415,396.00 |
| Dec 31, 2021 | 197,103.00 |
| Jun 30, 2021 | 521,784.00 |